{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T11:19:48Z","timestamp":1790421588826,"version":"4.1.0"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2018,3,21]],"date-time":"2018-03-21T00:00:00Z","timestamp":1521590400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100001545","name":"Children\u2019s Tumor Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001545","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,8,2]]},"DOI":"10.1093\/neuonc\/noy046","type":"journal-article","created":{"date-parts":[[2018,3,20]],"date-time":"2018-03-20T16:24:51Z","timestamp":1521563091000},"page":"1185-1196","source":"Crossref","is-referenced-by-count":39,"title":["EPH receptor signaling as a novel therapeutic target in NF2-deficient meningioma"],"prefix":"10.1093","volume":"20","author":[{"given":"Steven P","family":"Angus","sequence":"first","affiliation":[{"name":"Department of Pharmacology, Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, Chapel Hill, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet L","family":"Oblinger","sequence":"additional","affiliation":[{"name":"Center for Childhood Cancer and Blood Diseases, The Research Institute at Nationwide Children\u2019s Hospital"},{"name":"Department of Pediatrics, The Ohio State University College of Medicine, Columbus, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy J","family":"Stuhlmiller","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, Chapel Hill, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick A","family":"DeSouza","sequence":"additional","affiliation":[{"name":"Center for Genomic Medicine, Massachusetts General Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta L","family":"Beauchamp","sequence":"additional","affiliation":[{"name":"Center for Genomic Medicine, Massachusetts General Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke","family":"Witt","sequence":"additional","affiliation":[{"name":"Center for Genomic Medicine, Massachusetts General Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, Chapel Hill, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin T","family":"Jordan","sequence":"additional","affiliation":[{"name":"Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas S K","family":"Gilbert","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, Chapel Hill, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anat","family":"Stemmer-Rachamimov","sequence":"additional","affiliation":[{"name":"Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James F","family":"Gusella","sequence":"additional","affiliation":[{"name":"Center for Genomic Medicine, Massachusetts General Hospital, Boston, Massachusetts"},{"name":"Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott R","family":"Plotkin","sequence":"additional","affiliation":[{"name":"Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J","family":"Haggarty","sequence":"additional","affiliation":[{"name":"Center for Genomic Medicine, Massachusetts General Hospital, Boston, Massachusetts"},{"name":"Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long-Sheng","family":"Chang","sequence":"additional","affiliation":[{"name":"Center for Childhood Cancer and Blood Diseases, The Research Institute at Nationwide Children\u2019s Hospital"},{"name":"Department of Pediatrics, The Ohio State University College of Medicine, Columbus, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary L","family":"Johnson","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, Chapel Hill, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijaya","family":"Ramesh","sequence":"additional","affiliation":[{"name":"Center for Genomic Medicine, Massachusetts General Hospital, Boston, Massachusetts"},{"name":"Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Children\u2019s Tumor Foundation Synodos for NF2 Consortium","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"Bakker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"La Rosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wade","family":"Clapp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaishri","family":"Blakeley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Morrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley","family":"Welling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Gusella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Haggarty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Plotkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijaya","family":"Ramesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anat","family":"Stemmer-Rachamimov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long-Sheng","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Allaway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhishek","family":"Pratap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Guinney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sage","family":"Bionetworks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Fernandez-Valle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,3,21]]},"reference":[{"issue":"1","key":"key\n\t\t\t\t20180802061949_CIT0001","first-page":"24","article-title":"Consensus recommendations for current treatments and accelerating clinical trials for patients with neurofibromatosis type 2","volume":"158A","author":"Blakeley","year":"2012","journal-title":"Am J Med Genet A"},{"issue":"9","key":"key\n\t\t\t\t20180802061949_CIT0002","first-page":"599","article-title":"Neurofibromatosis 2 [Bilateral acoustic neurofibromatosis, central neurofibromatosis, NF2, neurofibromatosis type II]","volume":"11","author":"Evans","year":"2009","journal-title":"Genet Med"},{"issue":"4","key":"key\n\t\t\t\t20180802061949_CIT0003","first-page":"240","article-title":"Diagnosis, management, and new therapeutic options in childhood neurofibromatosis type 2 and related forms","volume":"22","author":"Ruggieri","year":"2015","journal-title":"Semin Pediatr Neurol"},{"issue":"5","key":"key\n\t\t\t\t20180802061949_CIT0004","first-page":"198","article-title":"Merlin and the ERM proteins\u2013regulators of receptor distribution and signaling at the cell cortex","volume":"19","author":"McClatchey","year":"2009","journal-title":"Trends Cell Biol"},{"issue":"1","key":"key\n\t\t\t\t20180802061949_CIT0005","first-page":"63","article-title":"The Nf2 tumor suppressor, merlin, functions in Rac-dependent signaling","volume":"1","author":"Shaw","year":"2001","journal-title":"Dev Cell"},{"issue":"19","key":"key\n\t\t\t\t20180802061949_CIT0006","first-page":"7932","article-title":"Validation of the p21-activated kinases as targets for inhibition in neurofibromatosis type 2","volume":"68","author":"Yi","year":"2008","journal-title":"Cancer Res"},{"issue":"15","key":"key\n\t\t\t\t20180802061949_CIT0007","first-page":"4250","article-title":"NF2\/merlin is a novel negative regulator of mTOR complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growth","volume":"29","author":"James","year":"2009","journal-title":"Mol Cell Biol"},{"issue":"15","key":"key\n\t\t\t\t20180802061949_CIT0008","first-page":"4235","article-title":"Loss of the tumor suppressor gene NF2, encoding merlin, constitutively activates integrin-dependent mTORC1 signaling","volume":"29","author":"L\u00f3pez-Lago","year":"2009","journal-title":"Mol Cell Biol"},{"issue":"1","key":"key\n\t\t\t\t20180802061949_CIT0009","first-page":"27","article-title":"The tumour-suppressor genes NF2\/Merlin and Expanded act through Hippo signalling to regulate cell proliferation and apoptosis","volume":"8","author":"Hamaratoglu","year":"2006","journal-title":"Nat Cell Biol"},{"issue":"6","key":"key\n\t\t\t\t20180802061949_CIT0010","first-page":"1342","article-title":"Spatial organization of Hippo signaling at the plasma membrane mediated by the tumor suppressor Merlin\/NF2","volume":"154","author":"Yin","year":"2013","journal-title":"Cell"},{"issue":"4","key":"key\n\t\t\t\t20180802061949_CIT0011","first-page":"477","article-title":"Merlin\/NF2 suppresses tumorigenesis by inhibiting the E3 ubiquitin ligase CRL4(DCAF1) in the nucleus","volume":"140","author":"Li","year":"2010","journal-title":"Cell"},{"issue":"2","key":"key\n\t\t\t\t20180802061949_CIT0012","first-page":"278","article-title":"Modeling NF2 with human arachnoidal and meningioma cell culture systems: NF2 silencing reflects the benign character of tumor growth","volume":"29","author":"James","year":"2008","journal-title":"Neurobiol Dis"},{"issue":"4","key":"key\n\t\t\t\t20180802061949_CIT0013","first-page":"493","article-title":"mTORC1 inhibition delays growth of neurofibromatosis type 2 schwannoma","volume":"16","author":"Giovannini","year":"2014","journal-title":"Neuro Oncol"},{"issue":"2","key":"key\n\t\t\t\t20180802061949_CIT0014","first-page":"313","article-title":"Phase II study of mTORC1 inhibition by everolimus in neurofibromatosis type 2 patients with growing vestibular schwannomas","volume":"122","author":"Goutagny","year":"2015","journal-title":"J Neurooncol"},{"issue":"2","key":"key\n\t\t\t\t20180802061949_CIT0015","first-page":"443","article-title":"A 4-year phase II study of everolimus in NF2 patients with growing vestibular schwannomas","volume":"133","author":"Goutagny","year":"2017","journal-title":"J Neurooncol"},{"issue":"4","key":"key\n\t\t\t\t20180802061949_CIT0016","first-page":"563","article-title":"Where is mTOR and what is it doing there","volume":"203","author":"Betz","year":"2013","journal-title":"J Cell Biol"},{"issue":"1","key":"key\n\t\t\t\t20180802061949_CIT0017","first-page":"9","article-title":"Defining the role of mTOR in cancer","volume":"12","author":"Guertin","year":"2007","journal-title":"Cancer Cell"},{"issue":"19","key":"key\n\t\t\t\t20180802061949_CIT0018","first-page":"16981","article-title":"A high-throughput kinome screen reveals serum\/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas","volume":"6","author":"Beauchamp","year":"2015","journal-title":"Oncotarget"},{"issue":"2","key":"key\n\t\t\t\t20180802061949_CIT0019","first-page":"307","article-title":"Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer","volume":"149","author":"Duncan","year":"2012","journal-title":"Cell"},{"issue":"3","key":"key\n\t\t\t\t20180802061949_CIT0020","first-page":"390","article-title":"Inhibition of lapatinib-induced kinome reprogramming in ERBB2-positive breast cancer by targeting BET family bromodomains","volume":"11","author":"Stuhlmiller","year":"2015","journal-title":"Cell Rep"},{"issue":"9","key":"key\n\t\t\t\t20180802061949_CIT0021","first-page":"2513","article-title":"Accurate proteome-wide label-free quantification by delayed normalization and maximal peptide ratio extraction, termed MaxLFQ","volume":"13","author":"Cox","year":"2014","journal-title":"Mol Cell Proteomics"},{"issue":"2","key":"key\n\t\t\t\t20180802061949_CIT0022","first-page":"792","article-title":"Histone deacetylase inhibitor AR-42 differentially affects cell-cycle transit in meningeal and meningioma cells, potently inhibiting NF2-deficient meningioma growth","volume":"73","author":"Burns","year":"2013","journal-title":"Cancer Res"},{"issue":"9","key":"key\n\t\t\t\t20180802061949_CIT0023","first-page":"1885","article-title":"Addressing accuracy and precision issues in iTRAQ quantitation","volume":"9","author":"Karp","year":"2010","journal-title":"Mol Cell Proteomics"},{"issue":"1","key":"key\n\t\t\t\t20180802061949_CIT0024","first-page":"39","article-title":"Therapeutic targeting of EPH receptors and their ligands","volume":"13","author":"Boyd","year":"2014","journal-title":"Nat Rev Drug Discov"},{"issue":"3","key":"key\n\t\t\t\t20180802061949_CIT0025","first-page":"274","article-title":"EPHA2 is a mediator of vemurafenib resistance and a novel therapeutic target in melanoma","volume":"5","author":"Miao","year":"2015","journal-title":"Cancer Discov"},{"issue":"5","key":"key\n\t\t\t\t20180802061949_CIT0026","first-page":"2037","article-title":"Genetic and pharmacologic inhibition of EphA2 promotes apoptosis in NSCLC","volume":"124","author":"Amato","year":"2014","journal-title":"J Clin Invest"},{"issue":"12","key":"key\n\t\t\t\t20180802061949_CIT0027","first-page":"2894","article-title":"Eph receptors and ephrins as targets for cancer therapy","volume":"16","author":"Xi","year":"2012","journal-title":"J Cell Mol Med"},{"issue":"16","key":"key\n\t\t\t\t20180802061949_CIT0028","first-page":"3327","article-title":"Proteolysis of EphA2 converts it from a tumor suppressor to an oncoprotein","volume":"75","author":"Koshikawa","year":"2015","journal-title":"Cancer Res"},{"issue":"8","key":"key\n\t\t\t\t20180802061949_CIT0029","first-page":"937","article-title":"EphA2 is a key effector of the MEK\/ERK\/RSK pathway regulating glioblastoma cell proliferation","volume":"28","author":"Hamaoka","year":"2016","journal-title":"Cell Signal"},{"key":"key\n\t\t\t\t20180802061949_CIT0030","first-page":"7679","article-title":"Crucial roles of RSK in cell motility by catalysing serine phosphorylation of EphA2","volume":"6","author":"Zhou","year":"2015","journal-title":"Nat Commun"},{"issue":"5","key":"key\n\t\t\t\t20180802061949_CIT0031","first-page":"624","article-title":"Therapeutic advances for the tumors associated with neurofibromatosis type 1, type 2, and schwannomatosis","volume":"18","author":"Blakeley","year":"2016","journal-title":"Neuro Oncol"},{"issue":"13","key":"key\n\t\t\t\t20180802061949_CIT0032","first-page":"5236","article-title":"Dissecting and targeting the growth factor-dependent and growth factor-independent extracellular signal-regulated kinase pathway in human schwannoma","volume":"68","author":"Ammoun","year":"2008","journal-title":"Cancer Res"},{"issue":"5","key":"key\n\t\t\t\t20180802061949_CIT0033","first-page":"649","article-title":"Regulation of mTOR complex 2 signaling in neurofibromatosis 2-deficient target cell types","volume":"10","author":"James","year":"2012","journal-title":"Mol Cancer Res"},{"issue":"4","key":"key\n\t\t\t\t20180802061949_CIT0034","first-page":"527","article-title":"A tight junction-associated Merlin-angiomotin complex mediates Merlin\u2019s regulation of mitogenic signaling and tumor suppressive functions","volume":"19","author":"Yi","year":"2011","journal-title":"Cancer Cell"},{"issue":"10","key":"key\n\t\t\t\t20180802061949_CIT0035","first-page":"2516","article-title":"Molecular pathways: adaptive kinome reprogramming in response to targeted inhibition of the BRAF-MEK-ERK pathway in cancer","volume":"20","author":"Johnson","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"3","key":"key\n\t\t\t\t20180802061949_CIT0036","first-page":"248","article-title":"mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling","volume":"1","author":"Rodrik-Outmezguine","year":"2011","journal-title":"Cancer Discov"},{"key":"key\n\t\t\t\t20180802061949_CIT0037","article-title":"Chen B, Xu X, Luo J, Wang H, Zhou S. Rapamycin enhances the anti-cancer effect of dasatinib by suppressing Src\/PI3K\/mTOR pathway in NSCLC cells. PLoS One. 2015;10(6):e0129663"},{"key":"key\n\t\t\t\t20180802061949_CIT0038","article-title":"Janes MR, Vu C, Mallya S, et al. Efficacy of the investigational mTOR kinase inhibitor MLN0128\/INK128 in models of B-cell acute lymphoblastic leukemia. Leukemia. 2013;27(3):586\u2013594"}],"container-title":["Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/20\/9\/1185\/25406387\/noy046.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,8,2]],"date-time":"2018-08-02T06:20:35Z","timestamp":1533190835000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article\/20\/9\/1185\/4947870"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,21]]},"references-count":38,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2018,3,21]]},"published-print":{"date-parts":[[2018,8,2]]}},"URL":"https:\/\/doi.org\/10.1093\/neuonc\/noy046","relation":{},"ISSN":["1522-8517","1523-5866"],"issn-type":[{"value":"1522-8517","type":"print"},{"value":"1523-5866","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,9]]},"published":{"date-parts":[[2018,3,21]]}}}